POST Online Media Lite Edition


NEWLY REPORTED COVID-19 CASES (11.19.2021, 4:50pm CEST, WHO):   India 11,106    Brazil 11,977    United Kingdom 46,858    Russia 37,156    Turkey 22,234    France 19,840    Argentina 1,553    Germany 52,970    Spain 3,932    Columbia 2,257    Italy 10,645    Mexico 3,836    Ukraine 20,050    Poland 23,242    Philippines 1,297    Malaysia 6,380    Netherlands 23,680    Peru 1,370    Thailand 6,855    Czechia 13,374    Canada 2,448    Romania 3,076    Chile 2,611    Serbia 3,219    Sweden 1,210    Portugal 2,398    Vietnam 10,223    Kazakhstan 1,272    Austria 14,212    Hungary 11,289    Greece 7,276    Georgia 4,278    Bulgaria 2,785    Belarus 1,844    Slovakia 7,418    Azerbaijan 2,124    Croatia 7,270    Bolivia 1,119    Ireland 4,646    Lithuania 1,847    Denmark 4,013    South Korea 3,034    Slovenia 3,662    Latvia 1,221    Laos 1,401    China 31    New Zealand 200    Australia 1,302   

Bad news: Gilead's coronavirus drug Remdesivir shows mixed results

Christian Fernsby |
Remdesivir, the drug developed as a treatment for coronavirus by Gilead Sciences, helped patients with moderate disease recover more quickly when they received it for five days, but the benefit was not statistically significant when given for 10 days, the company said Monday.

Article continues below

Topics: GILEAD   

An earlier study showed that patients with severe disease who received remdesivir recovered four days faster than similar patients who received placebo.

The patients in this study had what was termed "moderate" disease, meaning that they were hospitalized but did not need mechanical ventilation at any time. Unlike the study in more severe patients, this study did not give a placebo to those who did not receive the drug, meaning that both physicians and patients knew who was getting remdesivir and who wasn't.

Patients who received remdesivir for five days were 65% more likely to show improvement on a seven-point scale, where 1 was death and 7 was "not hospitalized," at the end of 11 days. Those who received remdesivir for 10 days were 31% more likely to have improved on the seven-point scale, but that difference was not statistically significant, meaning that it might have occurred by chance.

What to read next

Coronavirus: 79 year old Italian man successfully treated with experimental drug
U.S. approves remdesivir to treat coronavirus patients
Bad antibodies made good: The immune system's secret weapon uncovered